ARTICLE | Management Tracks
Plus: Dyne shares slip with CEO departing, and updates from Ardelyx and ProKidney
By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
March 26, 2024 1:38 AM UTC


AI-based medical research company Owkin Inc. named Jean-Jacques Bienaimé as chair. Bienaimé was CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) from 2005 until 2023, and remains on the company’s board. He is also a board member at Incyte Corp. (NASDAQ:INCY), Immunome Inc. (NASDAQ:IMNM) and BIO.
Joshua Brumm is departing muscle disease company Dyne Therapeutics Inc. (NASDAQ:DYN) as president and CEO to pursue a career in healthcare investing. He will be succeeded by John Cox, who was CEO of Repertoire Immune Medicines Inc. and rare disease company Bioverativ Inc. Shares of Dyne fell 8% to $26.06 on Monday…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651904/former-biomarin-ceo-bienaim-named-chair-of-owkin